Arrhythmias are irregular heart rhythms that are caused by a variety of reasons which includes age, medications, heart damage, and genetics. Cardiac resynchronization therapy is a procedure that implant a device in chest making heart’s chambers contract in an efficient and organized way. Cardiac resynchronization therapy uses a device called a biventricular pacemaker that delivers electrical signals the lower chambers of ventricles.
The global cardiac resynchronization therapy market report has been segmented on the basis of product, end user, and region. Increasing number of cases of heart failure globally is expected to drive the market growth over the forecast period. Furthermore, increasing number of approval and subsequent launch of the product by players in the market is expected to propel the market growth over the forecast period.
Based on product, the market is segmented based on CRT-Defibrillator(CRT-D) and CRT-Pacemaker (CRT-P). The CRT-Defibrillator segment contributes major market share and maintains its dominance over the forecast period owing to technological advancements and increasing number of product launches by players in the market.
Do Inquiry of the Report Here: https://marketresearch.biz/report/cardiac-resynchronization-therapy-market/#inquiry
Based on region, the global cardiac resynchronization therapy market is segmented into North America, Europe, Latin America, Asia Pacific and Middle East and Africa. North America contributes major market share and expected to maintain its dominance over the forecast period owing to well-developed health infrastructure and high adaptability of cardiac resynchronization therapy devices in the region. Asia Pacific is expected to witness rapid growth rate over the forecast period. This is attributed to the increasing prevalence of cardiovascular diseases and rapidly growing ageing population. In addition, increase in the demand of cardiac resynchronization therapy for treatment arrhythmia in China and India is excepted to fuel the market growth.
Some prominent players in the global cardiac resynchronization therapy market are Medtronic Plc., St. Jude Medical, Boston Scientific, Biotronik, LivaNova Plc, Merit Medical Systems, Inc., and Accellent Inc.